GRAIL, Inc. (GRAL)
79.72
-2.82
(-3.42%)
USD |
NASDAQ |
Aug 26, 11:48
GRAIL Profit Margin (Quarterly) : -246.7% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -246.7% |
| March 31, 2026 | -228.5% |
| December 31, 2025 | -227.5% |
| September 30, 2025 | -245.8% |
| June 30, 2025 | -320.7% |
| March 31, 2025 | -333.6% |
| December 31, 2024 | -253.8% |
| Date | Value |
|---|---|
| September 30, 2024 | -438.7% |
| June 30, 2024 | -4.96K% |
| March 31, 2024 | -819.3% |
| December 31, 2023 | -618.4% |
| September 30, 2023 | -4.30K% |
| June 30, 2023 | -861.3% |
| March 31, 2023 | -985.9% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -16.08% |
| Return on Assets | -13.86% |
| Return on Invested Capital | -15.67% |
| Gross Profit Margin (Quarterly) | -30.61% |
| Operating Margin (Quarterly) | -332.0% |
| Return on Net Operating Assets | -19.54% |